Hybrid device integrates a microfluidic chip for sample preparation and an optofluidic chip for optical detection of individual molecules of viral RNA
A team led by researchers at UC Santa Cruz has developed chip-based technology for reliable detection of Ebola virus and other viral pathogens. The system uses direct optical detection of viral molecules and can be integrated into a simple, portable instrument for use in field situations where rapid, accurate detection of Ebola infections is needed to control outbreaks.
Laboratory tests using preparations of Ebola virus and other hemorrhagic fever viruses showed that the system has the sensitivity and specificity needed to provide a viable clinical assay. The team reported their results in a paper published September 25 in Nature Scientific Reports.
An outbreak of Ebola virus in West Africa has killed more than 11,000 people since 2014, with new cases occurring recently in Guinea and Sierra Leone. The current gold standard for Ebola virus detection relies on a method called polymerase chain reaction (PCR) to amplify the virus’s genetic material for detection. Because PCR works on DNA molecules and Ebola is an RNA virus, the reverse transcriptase enzyme is used to make DNA copies of the viral RNA prior to PCR amplification and detection.
“Compared to our system, PCR detection is more complex and requires a laboratory setting,” said senior author Holger Schmidt, the Kapany Professor of Optoelectronics at UC Santa Cruz. “We’re detecting the nucleic acids directly, and we achieve a comparable limit of detection to PCR and excellent specificity.”
In laboratory tests, the system provided sensitive detection of Ebola virus while giving no positive counts in tests with two related viruses, Sudan virus and Marburg virus. Testing with different concentrations of Ebola virus demonstrated accurate quantification of the virus over six orders of magnitude. Adding a “preconcentration” step during sample processing on the microfluidic chip extended the limit of detection well beyond that achieved by other chip-based approaches, covering a range comparable to PCR analysis.
“The measurements were taken at clinical concentrations covering the entire range of what would be seen in an infected person,” Schmidt said.
Schmidt’s lab at UC Santa Cruz worked with researchers at Brigham Young University and UC Berkeley to develop the system. Virologists at Texas Biomedical Research Institute in San Antonio prepared the viral samples for testing.
The system combines two small chips, a microfluidic chip for sample preparation and an optofluidic chip for optical detection. For over a decade, Schmidt and his collaborators have been developing optofluidic chip technology for optical analysis of single molecules as they pass through a tiny fluid-filled channel on the chip. The microfluidic chip for sample processing can be integrated as a second layer next to or on top of the optofluidic chip.
Schmidt’s lab designed and built the microfluidic chip in collaboration with coauthor Richard Mathies at UC Berkeley who pioneered this technology. It is made of a silicon-based polymer, polydimethylsiloxane (PDMS), and has microvalves and fluidic channels to transport the sample between nodes for various sample preparation steps. The targeted molecules–in this case, Ebola virus RNA–are isolated by binding to a matching sequence of synthetic DNA (called an oligonucleotide) attached to magnetic microbeads. The microbeads are collected with a magnet, nontarget biomolecules are washed off, and the bound targets are then released by heating, labeled with fluorescent markers, and transferred to the optofluidic chip for optical detection.
Schmidt noted that the team has not yet been able to test the system starting with raw blood samples. That will require additional sample preparation steps, and it will also have to be done in a biosafety level 4 facility.
The Latest on: Ebola detection
via Google News
The Latest on: Ebola detection
- Gilead Sciences testing antiviral drug to treat coronaviruson February 3, 2020 at 1:31 pm
Gilead Sciences, a biopharmaceutical firm with an experimental drug called remdesivir that is used to treat the Ebola virus, said late Friday it is working with Chinese health authorities to see ...
- Purell Sued For Claiming Hand Sanitizer Prevents Flu, Ebolaon February 3, 2020 at 12:26 pm
"Defendant stops short of disclaiming the products' efficacy in preventing or curing Ebola, but couches its response in qualifying language," they said. "In other words, the products are effective ...
- Biotech Gilead Sciences testing antiviral drug to treat coronaviruson February 3, 2020 at 11:05 am
There is no cure for the deadly Wuhan coronavirus, but several big biotech companies are hoping they can treat the symptoms with existing antiviral medications. Gilead Sciences, a biopharmaceutical ...
- Biotech Companies Are Testing Drugs, Working on Vaccines to Combat Coronaviruson February 3, 2020 at 9:41 am
Gilead Sciences, a biopharmaceutical firm with an experimental drug called remdesivir that is used to treat the Ebola virus, said late Friday it is working with Chinese health authorities to see if ...
- The Wuhan Coronavirus is testing global public health in 3 major wayson February 3, 2020 at 9:12 am
Whether those handling this health crisis have learned from previous ones will be seen in the coming weeks, writes Stewart M. Patrick.
- China To Begin Testing Ebola Drug on Coronavirus Patientson February 3, 2020 at 6:43 am
A 2018 clinical trial found it was less effective than other drugs at treating Ebola, another viral disease. It’s totally understandable that people want a cure for the novel coronavirus as soon as ...
- Former SARS drug undergoing human testing in China to combat coronaviruson February 3, 2020 at 6:06 am
China has reportedly taken proactive measures to begin a clinical trial to test a drug to combat the Wuhan coronavirus outbreak as contamination efforts are still being pursued, according to Bloomberg ...
- Gilead +12% on coronavirus treatment testingon February 3, 2020 at 3:09 am
Shares of Gilead Sciences (NASDAQ:GILD) are up 12% in premarket action after formalizing an agreement with Chinese authorities to study the effectiveness of an experimental Ebola and SARS treatment on ...
- Trump’s Ebola Twitter freakout takes on a new light given his coronavirus responseon February 2, 2020 at 3:30 am
Obama is making the Ebola problem much worse than it needs to be in the U.S. by not halting flights from West Africa. Airport testing a joke — Donald J. Trump (@realDonaldTrump) October 10, 2014 ...
- Gilead working with China to test Ebola drug as new coronavirus treatmenton January 31, 2020 at 11:09 am
Gilead Sciences Inc ( GILD.O) said on Friday it provided its experimental Ebola therapy for use in a small number of patients with the coronavirus that has killed over 200 so far in China and is ...
via Bing News